CymaBay Therapeutics, a clinical-stage biopharma company, has entered into an exclusive license agreement with Kowa Pharmaceuticals America for the development and commercialization in the U.S. of arhalofenate, an oral, once-daily dual-acting drug candidate for the treatment of gout.   CymaBay will receive up to $15 million in upfront and near-term milestone payments and is eligible to receive up to an additional $190 million in payments based upon the achievement of specific development, reg...